ATE511508T1 - Verfahren zur kristallisation von (r)- oder (s)- lansoprazol - Google Patents

Verfahren zur kristallisation von (r)- oder (s)- lansoprazol

Info

Publication number
ATE511508T1
ATE511508T1 AT01998545T AT01998545T ATE511508T1 AT E511508 T1 ATE511508 T1 AT E511508T1 AT 01998545 T AT01998545 T AT 01998545T AT 01998545 T AT01998545 T AT 01998545T AT E511508 T1 ATE511508 T1 AT E511508T1
Authority
AT
Austria
Prior art keywords
lansoprazole
crystallization
crystal
production method
present
Prior art date
Application number
AT01998545T
Other languages
English (en)
Inventor
Hideo Hashimoto
Tadashi Urai
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18838123&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE511508(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE511508T1 publication Critical patent/ATE511508T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01998545T 2000-12-01 2001-11-30 Verfahren zur kristallisation von (r)- oder (s)- lansoprazol ATE511508T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000367757 2000-12-01
PCT/JP2001/010462 WO2002044167A1 (en) 2000-12-01 2001-11-30 Process for the crystallization of (r)- or (s)-lansoprazole

Publications (1)

Publication Number Publication Date
ATE511508T1 true ATE511508T1 (de) 2011-06-15

Family

ID=18838123

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01998545T ATE511508T1 (de) 2000-12-01 2001-11-30 Verfahren zur kristallisation von (r)- oder (s)- lansoprazol

Country Status (17)

Country Link
US (2) US7285668B2 (de)
EP (2) EP2345650A1 (de)
KR (3) KR100887912B1 (de)
CN (1) CN1254473C (de)
AT (1) ATE511508T1 (de)
AU (1) AU2002218506A1 (de)
CA (1) CA2436825C (de)
CY (1) CY1112347T1 (de)
DK (1) DK1337525T3 (de)
ES (1) ES2367419T3 (de)
HK (1) HK1054380B (de)
HU (1) HU229356B1 (de)
NO (1) NO326019B1 (de)
PL (3) PL399787A1 (de)
PT (1) PT1337525E (de)
TW (1) TWI290922B (de)
WO (1) WO2002044167A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020027315A1 (en) * 2000-03-10 2002-03-07 Parker Gerard E. Low-firing temperature method for producing Al2O3 bodies having enhanced chemical resistance
ES2511774T3 (es) 2000-05-15 2014-10-23 Takeda Pharmaceutical Company Limited Formas cristalinas de (R)-lansoprazol
JP2005533755A (ja) * 2002-03-27 2005-11-10 テバ ファーマシューティカル インダストリーズ リミティド ランソプラゾール多形及びその調製方法
CA2771725C (en) * 2002-10-16 2015-08-18 Takeda Pharmaceutical Company Limited Solid preparation comprising a non-toxic base and a proton pump inhibitor
CA2514575A1 (en) * 2003-01-31 2004-08-12 Teijin Pharma Limited Crystal of (23s)-1.alpha.-hydroxy-27-nor-25-methylenevitamin d3-26,23-lactone and process for producing the same
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US20050031700A1 (en) * 2003-07-18 2005-02-10 Sanatarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045062A1 (es) * 2003-07-18 2005-10-12 Santarus Inc Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
CA2554271A1 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
MXPA06011820A (es) * 2004-04-16 2006-12-15 Santarus Inc Combinacion de inhibidor de bomba de proton, agente regulador del ph y agente procinetico.
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP5563735B2 (ja) 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Ｐｐｉ多回剤形
EP1681056A1 (de) 2005-01-14 2006-07-19 Krka Tovarna Zdravil, D.D., Novo Mesto Verfahren zur Herstellung von Lansoprazol
BRPI0617987A2 (pt) * 2005-10-06 2011-08-16 Auspex Pharmaceuticals Inc composição, composição farmacêutica, forma de dosagem efervescente, composição farmacêutica oral de comprimidos unitários múltiplos, forma de dosagem farmacêutica de liberação prolongada, forma de dosagem farmacêutica revestida entérica, forma de dosagem farmacêutica estável para administração oral a sujeitos mamìferos, método para tratamento de doenças relacionadas a ácido gástrico pela inibição de secreção de ácido gástrico, método para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori, processo para preparar um composto da fórmula 3, processo para preparar um composto da fórmula 5, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relacionadas a ácido gástrico, pela inibição de secreção de ácido gástrico, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relecionadas a ácido gástrico pela inibição de secreção de ácido gástrico
CN101389316A (zh) 2005-12-28 2009-03-18 武田药品工业株式会社 控制释放固体制剂
KR100758600B1 (ko) * 2006-01-05 2007-09-13 주식회사 대웅제약 란소프라졸 결정형 ａ의 제조방법
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
WO2008081891A1 (ja) 2006-12-28 2008-07-10 Takeda Pharmaceutical Company Limited 口腔内崩壊性固形製剤
WO2008087665A2 (en) * 2007-01-18 2008-07-24 Matrix Laboratories Ltd Process for preparation of lansoprazole
KR101303813B1 (ko) 2007-04-16 2013-09-04 에스케이케미칼주식회사 라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법
BRPI0818286A2 (pt) * 2007-10-12 2020-08-11 Takeda Pharmaceuticals North America, Inc. métodos de tratamento de distúrbios gastrointestinais independente da ingestão de alimento.
EP2222663A1 (de) * 2007-12-18 2010-09-01 Watson Pharma Private Limited Verfahren zur herstellung von stabilem amorphem r-lansoprazol
JP2011513202A (ja) * 2008-03-10 2011-04-28 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
NZ589150A (en) 2008-05-14 2012-03-30 Watson Pharma Private Ltd Stable r (+) -lansoprazole amine salt and a process for preparing the same
WO2010039885A2 (en) * 2008-09-30 2010-04-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of dexlansoprazole
KR101321055B1 (ko) * 2008-11-14 2013-10-23 한미사이언스 주식회사 덱스란소프라졸의 신규 결정형 및 이를 포함하는 약학 조성물
IT1391776B1 (it) * 2008-11-18 2012-01-27 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo
WO2010095144A2 (en) * 2009-02-04 2010-08-26 Msn Laboratories Limited Process for the preparation of proton pump inhibitors
IT1392813B1 (it) * 2009-02-06 2012-03-23 Dipharma Francis Srl Forme cristalline di dexlansoprazolo
US20110009637A1 (en) * 2009-02-10 2011-01-13 Dario Braga Crystals of Dexlansoprazole
WO2011004387A2 (en) * 2009-06-18 2011-01-13 Matrix Laboratories Ltd Process for the preparation of dexlansoprazole polymorphic forms
IT1395118B1 (it) * 2009-07-29 2012-09-05 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo cristallino
AU2011210328A1 (en) 2010-01-29 2012-08-16 Ranbaxy Laboratories Limited Process for the preparation of crystalline forms of dexlansoprazole
AU2011234001B2 (en) 2010-03-31 2014-08-28 Sun Pharmaceutical Industries Limited Salts of dexlansoprazole and their preparation
US8853411B2 (en) 2010-03-31 2014-10-07 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
WO2012001705A2 (en) 2010-06-29 2012-01-05 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
CA2819460C (en) 2010-12-03 2017-08-01 Takeda Pharmaceutical Company Limited Orally disintegrating tablet
SG10201602311XA (en) 2010-12-27 2016-04-28 Takeda Pharmaceutical Orally disintegrating tablet
WO2012104805A1 (en) 2011-02-01 2012-08-09 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
US20140357870A1 (en) 2011-06-21 2014-12-04 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
CN102234265B (zh) * 2011-08-08 2013-11-20 天津市汉康医药生物技术有限公司 兰索拉唑化合物
ES2561098T3 (es) 2011-11-30 2016-02-24 Takeda Pharmaceutical Company Limited Comprimido recubierto en seco
US9626793B2 (en) 2011-12-29 2017-04-18 Intel Corporation Variable depth compression
WO2013140120A1 (en) 2012-03-22 2013-09-26 Cipla Limited Glycerol solvate forms of (r) - 2 - [ [ [3 -methyl -4 (2,2, 2 - trifluoroethoxy) pyridin- 2 - yl] methyl] sulphinyl] - 1h - ben zimidazole
WO2013179194A1 (en) 2012-05-31 2013-12-05 Ranbaxy Laboratories Limited Process for the preparation of crystalline dexlansoprazole
MY184077A (en) 2013-05-21 2021-03-17 Takeda Pharmaceuticals Co Orally disintegrable tablet
CN103254174B (zh) * 2013-06-05 2014-06-11 湖北济生医药有限公司 一种兰索拉唑化合物及其药物组合物
JP6557946B2 (ja) 2013-06-20 2019-08-14 日本ポリプロ株式会社 プロピレン系ブロック共重合体
CN104958276A (zh) * 2015-07-30 2015-10-07 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃溃疡的药物兰索拉唑组合物胶囊
CN104997739A (zh) * 2015-08-31 2015-10-28 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化系统疾病的药物兰索拉唑组合物冻干粉针剂
CN105399728B (zh) * 2015-12-20 2017-11-28 寿光富康制药有限公司 一种适用于工业化生产的右兰索拉唑的处理方法
CN106279107A (zh) * 2016-08-10 2017-01-04 成都尚药科技有限公司 一种右旋兰索拉唑晶型的制备方法
CN106749182A (zh) * 2016-11-08 2017-05-31 山东裕欣药业有限公司 一种右旋兰索拉唑晶型化合物及其制备方法
IT201700050223A1 (it) 2017-05-09 2018-11-09 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo cristallino
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
DK171989B1 (da) * 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
JPH1085502A (ja) * 1996-09-19 1998-04-07 Konica Corp 晶析方法
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
JP3828648B2 (ja) 1996-11-14 2006-10-04 武田薬品工業株式会社 ２−（２−ピリジルメチルスルフィニル）ベンズイミダゾール系化合物の結晶およびその製造法
TR199901101T2 (xx) * 1996-11-22 1999-07-21 The Procter & Gamble Company Gastroenstentinal hastal�klar�n tedavisine y�nelik bizmut ve nsaid i�eren bile�imler.
WO1999038512A1 (en) * 1998-01-30 1999-08-05 Sepracor Inc. S-lansoprazole compositions and methods
TWI289557B (en) * 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
JP4536905B2 (ja) * 1999-06-17 2010-09-01 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
JP3283252B2 (ja) * 1999-06-17 2002-05-20 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
AU5705700A (en) * 1999-06-30 2001-01-22 Takeda Chemical Industries Ltd. Crystals of benzimidazole compounds
JP2001039975A (ja) * 1999-07-26 2001-02-13 Eisai Co Ltd スルホキシド誘導体の結晶およびその製造法
WO2001014366A1 (fr) 1999-08-25 2001-03-01 Takeda Chemical Industries, Ltd. Procede de preparation de derives optiquement actifs de sulfoxyde
EP1277752B1 (de) 2000-04-28 2006-11-22 Takeda Pharmaceutical Company Limited Verfahren zur herstellung von optisch-aktiven sulfoxid-derivaten
ES2511774T3 (es) 2000-05-15 2014-10-23 Takeda Pharmaceutical Company Limited Formas cristalinas de (R)-lansoprazol
CN1117747C (zh) * 2000-06-19 2003-08-13 中国科学院成都有机化学研究所 光学纯兰索拉唑的制备方法

Also Published As

Publication number Publication date
ES2367419T3 (es) 2011-11-03
HUP0400781A3 (en) 2010-03-29
KR20100002278A (ko) 2010-01-06
CN1478086A (zh) 2004-02-25
KR20090003348A (ko) 2009-01-09
PT1337525E (pt) 2011-09-01
KR100939948B1 (ko) 2010-02-04
WO2002044167A1 (en) 2002-06-06
KR20030060967A (ko) 2003-07-16
HK1054380A1 (de) 2003-11-28
NO326019B1 (no) 2008-09-01
HK1054380B (zh) 2012-01-27
PL362801A1 (en) 2004-11-02
EP1337525B8 (de) 2011-10-05
NO20032437L (no) 2003-07-17
US20040049045A1 (en) 2004-03-11
HU229356B1 (en) 2013-11-28
PL409463A1 (pl) 2016-02-15
CY1112347T1 (el) 2015-12-09
CA2436825A1 (en) 2002-06-06
DK1337525T3 (da) 2011-09-19
EP1337525A1 (de) 2003-08-27
PL214684B1 (pl) 2013-09-30
HUP0400781A2 (hu) 2004-07-28
EP2345650A1 (de) 2011-07-20
PL399787A1 (pl) 2012-11-05
AU2002218506A1 (en) 2002-06-11
EP1337525B1 (de) 2011-06-01
US20080306118A1 (en) 2008-12-11
TWI290922B (en) 2007-12-11
US7285668B2 (en) 2007-10-23
NO20032437D0 (no) 2003-05-28
CA2436825C (en) 2011-01-18
CN1254473C (zh) 2006-05-03
KR100887912B1 (ko) 2009-03-12

Similar Documents

Publication Publication Date Title
ATE511508T1 (de) Verfahren zur kristallisation von (r)- oder (s)- lansoprazol
DE60014047D1 (de) Verfahren zur reinigung von milchsäure auf industrieller basis
DE3886297D1 (de) Verfahren zur Herstellung von hochreinem Sauerstoffgas aus Luft.
ATE96167T1 (de) Verfahren zur kristallisation von enzymen.
DE60201480D1 (de) Verfahren zur Herstellung von hochreinem Xylylendiamin
DE60235089D1 (de) Verfahren zur stabilisierung von reduziertem coenzym q10 und verfahren zur sauren kristallisation
DE60105113D1 (de) Verfahren zur Herstellung von einem Kristallepoxid
DE60316791D1 (de) Verfahren zur aufreinigung von lanzoprazol
ATE246692T1 (de) Verfahren zur reinigung von phosphatidylserin
DE3851022T2 (de) Verfahren zur Herstellung von verzweigten Fructo-Oligosacchariden.
ATE150746T1 (de) Methode zur handhabung von maleimiden
DE60019723D1 (de) Eine methode zur herstellung von verbindungen der formel 1 und derivaten
ATE199556T1 (de) Verfahren zur fraktionierung von deacylierten glycerophospholipiden
ATE328878T1 (de) Verfahren zur reinigung von liponsäure
DE602004028230D1 (de) Verfahren zur Reinigung und zur Herstellung von Phosphorsäure
ATE191508T1 (de) Mikrobiologisches verfahren zur herstellung von 1-ungesättigten, 17-beta-carboxysubstituierten 3- oxo-4-azaandrostan-3-onen
ATE206584T1 (de) Eine zusammensetzung und ein verfahren zur foerderung der pflanzenproduktion und/oser zur eliminierung von unguenstigen umwelteinfluessen bei der pflanzenzucht
TH57580B (th) วิธีการผลิตผลึก
DE68916172T2 (de) Verfahren zur kristallisierung und reinigung zur herstellung von stabilen kristallen von tetrakis 3-(3,5-di-tertiary-butyl-4-hydroxyphenyl)propionyloxymethyl-methan auf industrieller basis.
ATE281428T1 (de) Verfahren zur herstellung von methoxyimino- essigsäureamiden
DE69917240D1 (de) Verfahren zur Herstellung von gereinigter Sorbinsäure
DE3882744D1 (de) Methode zur herstellung von indan-derivaten.
DE60007201D1 (de) Verfahren zur Herstellung von Ascorbinsaüre-2-Monophosphat salz
DE50207808D1 (de) Verfahren zur herstellung einer salzfreien, wässrigen hydroxylaminlösung
DE50000755D1 (de) Verfahren zur herstellung von 4,4- dimethyl -3beta- hydroxypregna -8,14-dien-21- carbonsäureestern und zwischenprodukte im verfahren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1337525

Country of ref document: EP